Bio-Rad Laboratories Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.6B+0.9% YoYTTM through 30 Jun 2026
Net Income $222.4MTTM through 30 Jun 2026
Free Cash Flow $353.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 51.9% |
| EBITDA Margin | 3.6% |
| Operating Margin | 1.8% |
| Net Margin | 8.6% |
Returns
3.1%ROE
2.2%ROA
3.0%ROIC
Balance Sheet Health
Debt / Equity0.11x
Current Ratio3.14x
Net Debt$286M
Cash & Equivalents$517M
Quality Metrics
Altman Z-Score3.58
Piotroski F-Score6 / 9
FCF Margin13.6%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $2.6B
Diluted EPS$8.21TTMFY2025: $27.85
Dividend
No dividend
Capital Allocation
R&D Spend$265.7M
Capex Intensity5.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Clinical Diagnostics | $1.6B | +0.8% | View detailsClinical Diagnostics returned to growth in 2025, supported by strength in the quality control and blood typing portfolios, though partially offset by lower reimbursement rates for diabetes testing in China. |
| Life Science | $1B | -0.7% | View detailsLife Science segment sales declined in 2025, primarily driven by a constrained academic research and biotech funding environment, which weighed heavily on instrument demand. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.